Having trouble accessing articles? Reset your cache.

ITCA 650: Final Phase II data

Final data from an open-label, U.S. Phase II trial in 155 Type II diabetics on stable metformin showed that 20, 40, 60 and 80 µg/day ITCA 650 implanted subcutaneously reduced mean HbA1c from

Read the full 335 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE